Items where authors include "O'Brien, S"
Up a levelArticle
de Silva, TI orcid.org/0000-0002-6498-9212, Liu, G, Lindsey, BB orcid.org/0000-0003-4227-2592 et al. (1010 more authors) (2021) The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience, 24 (11). 103353. ISSN 2589-0042
Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736
Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736
Glasbey, JC, Nepogodiev, D, Omar, O et al. (3453 more authors) (2020) Delaying surgery for patients with a previous SARS-CoV-2 infection. British Journal of Surgery, 107 (12). e601-e602. ISSN 0007-1323
Munir, T, Brown, JR, O'Brien, S et al. (17 more authors) (2019) Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 94 (12). pp. 1353-1363. ISSN 0361-8609
Fox, TA, Horne, GA, Craddock, C et al. (6 more authors) (2019) Trial re-investment to build better research for better impact. The Lancet, 394 (10199). pp. 635-636. ISSN 0140-6736
Barrientos, JC, O'Brien, S, Brown, JR et al. (25 more authors) (2018) Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 18 (12). 803-813.e7. ISSN 2152-2650
Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403, O'Brien, S et al. (27 more authors) (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia, 32. pp. 83-91. ISSN 0887-6924
Barr, PM, Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (19 more authors) (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 129 (19). pp. 2612-2615. ISSN 0006-4971